Navidea Biopharmaceuticals said it has sold shares to JPMorgan Chase & Co.'s asset management unit along with another investor. The company anticipates raising $5.1 million from the move. "We are pleased to be able to capitalize on this opportunity to strengthen our institutional ownership base as we work toward the launch of our first commercial radiopharmaceutical agent, Lymphoseek," said Navidea President and CEO Mark Pykett.

Related Summaries